181 related articles for article (PubMed ID: 23466553)
1. Cinacalcet improves endothelial dysfunction and cardiac hypertrophy in patients on hemodialysis with secondary hyperparathyroidism.
Choi SR; Lim JH; Kim MY; Hong YA; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Nephron Clin Pract; 2012; 122(1-2):1-8. PubMed ID: 23466553
[TBL] [Abstract][Full Text] [Related]
2. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
6. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
9. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
11. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
13. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
16. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice.
Bover J; Perez R; Molina M; Benavides B; Ariza F; Miguel JL; Tornero F; Torregrosa JV;
Nephron Clin Pract; 2011; 118(2):c109-21. PubMed ID: 21150219
[TBL] [Abstract][Full Text] [Related]
20. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]